NCT04990609RecruitingPhase 2
EUS-RFA PANCARDINAL-1 Trial
A Single-arm Phase II Study to Evaluate the Safety and Efficacy of Combination Systematic Chemotherapy and Multiple Rounds of Endoscopic Ultrasound-guided Radiofrequency Ablation in Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 29 Jul 2026
Brief summary (registry, in English)
The objectives of this study are to determine the feasibility, tolerability, and treatment effect of endoscopic ultrasound (EUS) radiofrequency ablation (RFA) plus standard-of-care neoadjuvant chemotherapy (NAC) in the treatment of pancreatic ductal adenocarcinoma (PDAC). Endoscopic ultrasound (EUS) radiofrequency ablation (RFA) and neoadjuvant chemotherapy (NAC) will be performed before tumor resection surgery, with the goal of shrinking a tumor or stopping the spread of cancer so that surgery might be less invasive and more effective.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 2 Feb 2021
- Start date
- Aug 2021
- Primary completion date
- Dec 2026
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Diseases
- Pancreatic cancer
- NCT number
- NCT04990609
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 60
- From Aug 2021 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Male or female patients \< 18 years of age
Other
- No permanent street address or telephone number
- Pregnant patients
- Inmates or prisoners
- Unable to provide informed consent
Who the study is looking for
- Diagnosed and histologically-confirmed PDAC by biopsy
- Permanent street address
- Consent to study participation
- Axial CT scan consistent with PDAC
- No prior chemotherapy or less than 2 months of pre-operative chemotherapy for PDAC
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Hermann Hospital Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.